Mindset Pharma Announces Inclusion in NYSE Listed AdvisorShares Psychedelics Exchange Traded Fund (ETF)
23 Septiembre 2021 - 6:30AM
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF)
(OTCQB: MSSTF) ("Mindset" or the "Company"), a drug
discovery and development company focused on creating optimized and
patentable next-generation psychedelic medicines to treat
neurological and psychiatric disorders with unmet needs, today
announced that it has been included in the AdvisorShares
Psychedelics ETF traded on the NYSE Arca under the ticker symbol
“PSIL.”
PSIL is an actively managed exchange-traded product that invests
in the emerging psychedelic drugs sector. The PSIL offers exposure
to biotechnology, pharmaceutical and life sciences companies
deriving the majority of their net revenue or devoting the majority
of their assets to psychedelic drugs, and only holds companies that
they see as leading the way in this industry.
“Mindset’s inclusion in the actively-managed
PSIL is another positive step in building awareness and education
for the exciting developments at Mindset, as well as the
psychedelics industry as a whole. We are thrilled to be considered
a leader in the space and appreciate the support from the capital
markets as we progress our differentiated pipeline of next
generation psychedelic-inspired drug candidates towards the
clinic,” said James Lanthier, Chief Executive Officer of
Mindset.
For more information, please
contact:
Investor Contact: Allison Soss/Tim ReganKCSA
Strategic CommunicationsEmail: MindSet@kcsa.com Phone:
212-896-1267/ 347-487-6788
Company Contact:James Lanthier, CEOEmail:
jlanthier@mindsetpharma.com
Jason Atkinson, VP, Corporate DevelopmentEmail:
jatkinson@mindsetpharma.com Phone: 416-479-4094
About Mindset Pharma Inc.Mindset Pharma Inc. is
a drug discovery and development company focused on creating
optimized and patentable next-generation psychedelic medicines to
treat neurological and psychiatric disorders with unmet needs.
Mindset was established in order to develop next generation
pharmaceutical assets that leverage the breakthrough therapeutic
potential of psychedelic drugs. Mindset is developing several novel
families of next generation psychedelic compounds, as well as an
innovative process to chemically synthesize psilocybin as well as
its own proprietary compounds.
For further information on Mindset, please visit our website at
www.mindsetpharma.com.
Forward-Looking Information
This news release contains certain
"forward-looking information" within the meaning of applicable
securities law. Forward looking information is frequently
characterized by words such as "plan", "expect", "project",
"intend", "believe", "anticipate", "estimate", "may", "will",
"would", "potential", "proposed" and other similar words, or
statements that certain events or conditions "may" or "will" occur.
These statements are only predictions. Forward-looking information
is based on the opinions and estimates of management at the date
the information is provided and is subject to a variety of risks
and uncertainties and other factors that could cause actual events
or results to differ materially from those projected in the
forward-looking information. Additional information regarding risks
and uncertainties relating to the Company's business are contained
under the heading "Risk Factors" in the Company's annual
information form for the financial year ended June 30, 2020 dated
March 5, 2021. The forward-looking information included in this
news release is made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking information to reflect new information, subsequent
events or otherwise, except as required by applicable law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS
REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS
RELEASE.
AdvisorShares Tr (NYSE:PSIL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
AdvisorShares Tr (NYSE:PSIL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024